1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ADR120S, Inc.

ADR120S, Inc.

3750.T
ADR120S, Inc.JP flagTokyo Stock Exchange
830.00
JPY
+32.00
- -
7.41BMarket Cap
ADR120S, Inc.
3750.T
(Tokyo Stock Exchange)

Recent

price

830.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,053.28
1,208.11
613.01
686.1
566.96
373.61
381.75
76.89
286.71
175.86
169.63
151.26
240.21
174.77
13.69
- -
78.16
Revenue per Share
213.71
-49.75
40.3
59.36
16.81
4.75
-65.81
66.25
88.3
47.58
-101.64
-8.79
-118.71
15.47
-239.7
- -
65.13
Basic EPS, GAAP
56.65
-135.3
-192.6
-156.22
-2.19
-57.63
249.65
37.46
-409.78
77.34
-12.08
-41.66
-22.18
-130.87
-111.46
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
10
20
8.2
- -
- -
- -
- -
- -
- -
Dividend per Share
1,344.89
1,259.53
897.67
813.64
599.09
604.24
-40.04
39.38
202.16
229.76
78.59
63.74
-55.66
-40.18
-282.08
- -
-90.81
Book Value per Share
387.21
338.02
456.72
579.21
438.48
444.95
384.77
452.51
535.84
442.98
335.74
336.81
220.4
310.73
70.4
- -
260.27
Tangible Book Value per Share
2
2
4
5
7
7
7
7
7
7
8
9
9
9
9
- -
9
Basic Weighted Avg Shares
2,536
2,908
2,316
3,531
4,076
2,684
2,693
522
1,925
1,180
1,388
1,336
2,145
1,560
122
51
698
Sales/Revenue/Turnover
4.82
3.76
14.62
19.72
20.56
-0.66
-14.8
24.98
15.24
-10.94
-52.7
-34.62
-37.04
-49.52
-660.28
-1,777.23
-59.99
Operating Margin (%)
229
249
168
77
68
17
9
10
50
174
308
321
331
254
50
1
- -
Depreciation Expense
514
-120
152
306
121
34
-464
450
593
319
-832
-78
-1,060
138
-2,140
-397
581
Net Income, GAAP
2.28
- -
- -
- -
42
54.93
- -
0.41
0.26
0.58
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
20.29
-4.12
6.57
8.65
2.96
1.27
-17.24
86.16
30.8
27.06
-59.92
-5.81
-49.42
8.85
-1,751.24
-778.43
83.32
Profit Margin (%)
219
380
1,508
2,524
2,952
3,161
2,680
873
6,370
5,667
5,535
2,034
215
892
25
124
445
Working Capital
473
481
- -
- -
- -
- -
- -
- -
2,890
8,219
8,013
8,551
7,606
2,347
2,294
- -
2,321
LT Debt
1,496
1,256
1,789
3,031
3,193
3,226
2,717
3,075
3,601
3,833
3,548
3,716
2,657
2,796
631
22
2,339
Total Equity
3.32
- -
- -
- -
14.54
-0.23
- -
3.25
4.81
-1.32
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
14.11
- -
- -
- -
2.91
0.81
- -
41.9
17.72
5.06
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
26.96
-3.82
4.74
8.06
2.85
0.79
- -
- -
72.97
22.03
-76.13
-12.87
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
125
- -
54
LT Borrowings
2,347
- -
2,321
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
- -
9
Market Capitalization
8,661
8,794
7,509

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
1,428
- -
796
Cash, Cash Equivalents & STI
1,038
- -
522
Accounts Receivable, Net
58
- -
13
Inventories
104
- -
107
Total Current Liabilities
536
- -
352
Payables & Accruals
- -
- -
- -
ST Debt
125
- -
54
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-17.9%
-38.5%
-96.51%
Free Cash Flow
-135%
136%
-21.14%
Net Income, GAAP
-270.1%
-133.78%
-81.45%
Sales/Revenue/Turnover
4.63%
-24.18%
-58.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
472
390
549
149
1,560
2025
- -
- -
- -
- -
122
2026
- -
- -
- -
- -
51

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-18.06
- -
- -
- -
15.47
2025
- -
- -
- -
- -
-239.7
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Pharmiva AB (publ) (PHARM.ST)
Medigen Vaccine Biologics Corp. (6547.TWO)
Epizyme, Inc. (EPZM)
Ensysce Biosciences, Inc. (ENSCW)
Concord Biotech Limited (CONCORDBIO.BO)
YS Biopharma Co., Ltd. (YS)
Business
ADR120S, Inc. (TSE: 3750) develops, produces and sells adipose-derived regenerative cell (ADRC) therapy medical devices and related technology in Japan; core products include the Celusion centrifuge and Celusion cell therapy kits; product pipeline features ECCI-50 for male stress urinary incontinence and liver cirrhosis, Cyt-006 to prevent postoperative adhesion in primary rectal cancer, alongside clinical research in anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, and erectile dysfunction. Incorporated in 2004 and headquartered in Tokyo, the company operates through Medical and Real Assets segments, with the latter focused on real estate investment, purchase and sales, hotel development, brokerage services, and property management. Recent developments include a name change from Cytori Cell Research Institute Inc., memoranda of understanding with China's Weilin Group and state-owned Guangcai Group for business collaboration, an exclusive license for high-concentration exosome production technology, establishment of subsidiaries including one in Saudi Arabia, a share transfer agreement on October 29, 2025 to acquire 71.51% of AthleteMed Corporation from EBISTRADE Inc., and sales of hospitality assets such as Fractal Hospitality Co. and Hotel Kanazawa Co. to Samty Hotel Management K.K. in 2024.